Applications
hpDNA™ is ideally suited to replace plasmid DNA in the production of AAV (adeno-associated virus) and Lentivirus by means of transient transfection in a producer cell line. hpDNA™ mitigates the risk of reverse packaging of bacterial sequences, can enhance viral genome packaging efficiency while achieving equivalent viral titres using less DNA input material.
Services
- hpDNA™ production of DNA templates required for AAV and Lentivirus production
- Off the shelf Rep-Cap, Helper and reporter AAV constructs for a range of serotypes
Due to their open ended, 3’ end, opDNA™ and oeDNA™ is ideally suited for production of mRNA through in vitro transcription processes. Unlike other synthetic templates or pDNA, opDNA™ and oeDNA™ templates do not require linearisation and produce high yields of mRNA when applied directly in IVT processes. Further, these constructs are free from bacterial sequences or contaminants as it is made entirely enzymatically. opDNA™ and oeDNA™ are compatible with both enzymatic and co-transcriptional capping strategies. Additionally, long and continuous poly-A sequences can be coded into the DNA templates, avoiding the need for enzymatic tailing, resulting in products with well-defined poly A tails.
Services
- Rapid synthesis of custom opDNA™ and oeDNA™ templates including larger samRNA templates suitable for use in GMP IVT processes
- Generation of opDNA™ and oeDNA™ template libraries for screening
- Off-the-shelf reporter mRNA constructs for testing and validation
- Production of custom mRNA constructs, including samRNA
- IVT Platform support
oeDNA™ can be used for genome editing applications as a homology directed repair (HDR) template. The high-purity, linear DNA product can be custom designed with varying lengths of homology arms for use in in vitro, ex vivo and in vivo applications.
Services
- Rapid synthesis of custom oeDNA™ templates for gene editing applications
- Generation of osDNA™ and hpDNA™ template libraries for screening
osDNA™ is ideally suited for use in DNA vaccine applications. By introducing DNA modifications during the manufacturing process, we have demonstrated that we can tune the immunostimulatory properties of osDNA™. Lower doses of osDNA™ produce enhanced immune responses compared to plasmid DNA. osDNA™ is compatible with a variety of gene delivery technologies including electroporation (EP), LNPs and our own Hermes™ non-viral delivery platform.
Services
- Off-the shelf reporter genes for validation (GFP, Luciferase)
- Rapid synthesis of custom osDNA™ templates for use in DNA vaccine applications
- Generation of osDNA™ template libraries for screening
Hermes™ is our proprietary delivery platform for nucleic acid and protein payloads. The non-viral nanoparticle comprises an interchangeable targeting moiety that allows for preferential uptake in a specific cell or target tissue of interest and mitigates off target effects. The particles have low immunogenicity, enabling repeat dosing strategies, and are suitable for various in vivo routes of administration. The manufacturing process is scalable and cost-effective, driven by self-assembly processes.
Services
- Development of cell specific targeting and in vitro validation
- Encapsulation of custom payloads are existing Hermes™ particles
- In vitro and In vivo validation services
- Manufacture for pre-clinical in vivo studies
For more information and how our technologies can help you, please contact us
